Neovasc Inc logo

NVCN - Neovasc Inc Share Price

C$3.93 0.1  2.9%

Last Trade - 25/05/20

Micro Cap
Market Cap £25.0m
Enterprise Value £28.3m
Revenue £1.68m
Position in Universe 876th / 2657
Unlock NVCN Revenue
Relative Strength (%)
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Financial Summary
FINANCIAL BRIEF: : For the three months ended 31 March 2020, Neovasc Inc revenues decreased 9% to $533K. Net loss decreased 52% to $4.1M. Revenues reflect Europe segment decrease of 7% to $480K, Rest of the World segment decrease of 21% to $53K. Lower net loss reflects Unrealized gain on derivative liability increase from $782K (expense) to $3.1M (income), Realized loss on exercise of warrants an decrease of 82% to $144K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


NVCN Revenue Unlock NVCN Revenue

Net Income

NVCN Net Income Unlock NVCN Revenue

Normalised EPS

NVCN Normalised EPS Unlock NVCN Revenue

PE Ratio Range

NVCN PE Ratio Range Unlock NVCN Revenue

Dividend Yield Range

NVCN Dividend Yield Range Unlock NVCN Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
NVCN EPS Forecasts Unlock NVCN Revenue
Profile Summary

Neovasc Inc. (Neovasc) is a specialty medical device company. The Company develops, manufactures and markets products for the cardiovascular marketplace. The Company's segment is the development, manufacture and marketing of medical devices. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer for the treatment of refractory angina, and tissue products. The Tiara is in preclinical/early clinical stage development to provide a minimally invasive transcatheter device for patients experiencing mitral regurgitation (MR) as a result of mitral heart valve disease. The Reducer is an hourglass-shaped, balloon-expandable, stainless steel, bare metal device, which is implanted in the coronary sinus, creating a restriction in venous outflow from the myocardium (the muscular layer of the heart wall). Neovasc produces Peripatch, a biological tissue product that is manufactured from pericardium.

Last Annual December 31st, 2019
Last Interim March 31st, 2020
Incorporated April 19, 2002
Public Since May 23, 2001
No. of Shareholders: n/a
No. of Employees: 98
Sector Healthcare
Industry Healthcare Equipment & Supplies
Exchange Toronto Stock Exchange
Shares in Issue 11,133,319
Free Float (0.0%)
Eligible for
NVCN Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for NVCN
Upcoming Events for NVCN
Similar to NVCN
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.